Kamada wins US patent for inhalable emphysema therapy

AAT-1 is a protein replacement therapy to treat congenital respiratory diseases, such congenital emphysema, bronchiectasis, and cystic fibrosis.

The US Office of Patents and Trademarks has awarded Kamada Ltd. (TASE: KMDA) a patent for the inhalable version of its Alpha 1 Antitrypsin (AAT-1) protein replacement therapy to treat congenital respiratory diseases.

The patent, "Alpha 1 Antitrypsin for Treating Exacerbation Episodes of Pulmonary Diseases", is for chronic obstruction pulmonary disease (COPD), which can refer to congenital emphysema and bronchiectasis, as well cystic fibrosis, and influenza.

The patent for inhalable AAT-1 comes six months after Kamada received a US patent for the cleaning and purification process of AAT-1.

Kamada CEO David Tsur said, "The US patent is further testimony to the company's innovation and proprietary technology and know-how. It fits in well with the company's goal of completing the final Phase II-III clinical trial of our next-generation inhalable AAT-1 treatment, and paves the way for creating a new business channel and the company's future growth.

Kamada's share price rose 2.6% in morning trading to NIS 31.04, giving a market cap of NIS 833 million.

Published by Globes [online], Israel business news - www.globes-online.com - on April 10, 2011

© Copyright of Globes Publisher Itonut (1983) Ltd. 2011

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018